Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cell membrane Single-pass type II membrane protein Cytoplasmic vesicle lumen Lysosome lumen Note=Is internalized into multivesicular bodies of secretory lysosomes after phosphorylation by FGR and monoubiquitination (PubMed:17164290). Colocalizes with the SPPL2A protease at the cell membrane (PubMed:17557115). ; SUBCELLULAR LOCATION: Tumor necrosis factor ligand superfamily member 6, soluble form: Secreted Note=May be released into the extracellular fluid by cleavage from the cell surface. ; SUBCELLULAR LOCATION: FasL intracellular domain: Nucleus Note=The FasL ICD cytoplasmic form is translocated into the nucleus. |
Domain |
PF00229 TNF(Tumour Necrosis Factor) family |
Function |
Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells (PubMed:26334989, PubMed:9228058). Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development (PubMed:9228058, PubMed:7528780, PubMed:9427603). Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses (By similarity). TNFRSF6/FAS-mediated apoptosis has also a role in the induction of peripheral tolerance (By similarity). Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis (PubMed:27806260). ; FUNCTION: Tumor necrosis factor ligand superfamily member 6, soluble form: Induces FAS-mediated activation of NF-kappa-B, initiating non-apoptotic signaling pathways (By similarity). Can induce apoptosis but does not appear to be essential for this process (PubMed:27806260). ; FUNCTION: FasL intracellular domain: Cytoplasmic form induces gene transcription inhibition. |
Biological Process |
GO:0001525 angiogenesis GO:0001654 eye development GO:0002237 response to molecule of bacterial origin GO:0006885 regulation of pH GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006925 inflammatory cell apoptotic process GO:0007032 endosome organization GO:0007033 vacuole organization GO:0007173 epidermal growth factor receptor signaling pathway GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0007423 sensory organ development GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors GO:0010623 programmed cell death involved in cell development GO:0010950 positive regulation of endopeptidase activity GO:0010952 positive regulation of peptidase activity GO:0016525 negative regulation of angiogenesis GO:0030002 cellular anion homeostasis GO:0030004 cellular monovalent inorganic cation homeostasis GO:0030320 cellular monovalent inorganic anion homeostasis GO:0030641 regulation of cellular pH GO:0030644 cellular chloride ion homeostasis GO:0032496 response to lipopolysaccharide GO:0038127 ERBB signaling pathway GO:0042058 regulation of epidermal growth factor receptor signaling pathway GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043523 regulation of neuron apoptotic process GO:0043525 positive regulation of neuron apoptotic process GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway GO:0045765 regulation of angiogenesis GO:0045851 pH reduction GO:0045862 positive regulation of proteolysis GO:0046666 retinal cell programmed cell death GO:0048388 endosomal lumen acidification GO:0048514 blood vessel morphogenesis GO:0048592 eye morphogenesis GO:0051402 neuron apoptotic process GO:0051452 intracellular pH reduction GO:0051453 regulation of intracellular pH GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0055064 chloride ion homeostasis GO:0055067 monovalent inorganic cation homeostasis GO:0055081 anion homeostasis GO:0055083 monovalent inorganic anion homeostasis GO:0070227 lymphocyte apoptotic process GO:0070231 T cell apoptotic process GO:0070265 necrotic cell death GO:0070266 necroptotic process GO:0070997 neuron death GO:0071887 leukocyte apoptotic process GO:0072577 endothelial cell apoptotic process GO:0090596 sensory organ morphogenesis GO:0097191 extrinsic apoptotic signaling pathway GO:0097296 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097300 programmed necrotic cell death GO:0097527 necroptotic signaling pathway GO:1901184 regulation of ERBB signaling pathway GO:1901186 positive regulation of ERBB signaling pathway GO:1901214 regulation of neuron death GO:1901216 positive regulation of neuron death GO:1901342 regulation of vasculature development GO:1901343 negative regulation of vasculature development GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1904019 epithelial cell apoptotic process GO:1904035 regulation of epithelial cell apoptotic process GO:1904037 positive regulation of epithelial cell apoptotic process GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000181 negative regulation of blood vessel morphogenesis GO:2000351 regulation of endothelial cell apoptotic process GO:2000353 positive regulation of endothelial cell apoptotic process GO:2001056 positive regulation of cysteine-type endopeptidase activity GO:2001233 regulation of apoptotic signaling pathway GO:2001234 negative regulation of apoptotic signaling pathway GO:2001235 positive regulation of apoptotic signaling pathway GO:2001236 regulation of extrinsic apoptotic signaling pathway GO:2001237 negative regulation of extrinsic apoptotic signaling pathway GO:2001267 regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:2001269 positive regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway |
Molecular Function |
GO:0005123 death receptor binding GO:0005125 cytokine activity GO:0005126 cytokine receptor binding GO:0005164 tumor necrosis factor receptor binding GO:0032813 tumor necrosis factor receptor superfamily binding |
Cellular Component |
GO:0005775 vacuolar lumen GO:0005901 caveola GO:0009897 external side of plasma membrane GO:0031983 vesicle lumen GO:0043202 lysosomal lumen GO:0044853 plasma membrane raft GO:0045121 membrane raft GO:0060205 cytoplasmic membrane-bounded vesicle lumen GO:0098552 side of membrane GO:0098589 membrane region GO:0098857 membrane microdomain |
KEGG |
hsa04010 MAPK signaling pathway hsa04014 Ras signaling pathway hsa04060 Cytokine-cytokine receptor interaction hsa04068 FoxO signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04210 Apoptosis hsa04650 Natural killer cell mediated cytotoxicity hsa04722 Neurotrophin signaling pathway |
Reactome |
R-HSA-109581: Apoptosis R-HSA-5218900: CASP8 activity is inhibited R-HSA-5357769: Caspase activation via extrinsic apoptotic signalling pathway R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-73887: Death Receptor Signalling R-HSA-8862803: Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models R-HSA-69416: Dimerization of procaspase-8 R-HSA-1643685: Disease R-HSA-75157: FasL/ CD95L signaling R-HSA-168256: Immune System R-HSA-6785807: Interleukin-4 and 13 signaling R-HSA-140534: Ligand-dependent caspase activation R-HSA-8863678: Neurodegenerative Diseases R-HSA-5357801: Programmed Cell Death R-HSA-5213460: RIPK1-mediated regulated necrosis R-HSA-5218859: Regulated Necrosis R-HSA-3371378: Regulation by c-FLIP R-HSA-5675482: Regulation of necroptotic cell death R-HSA-162582: Signal Transduction R-HSA-449147: Signaling by Interleukins |
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between FASLG and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between FASLG and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of FASLG in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of FASLG in various data sets.
|
Points in the above scatter plot represent the mutation difference of FASLG in various data sets.
|
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FASLG. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FASLG. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FASLG. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FASLG. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of FASLG expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between FASLG and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | FASLG |
Name | Fas ligand (TNF superfamily, member 6) |
Aliases | FasL; CD178; APT1LG1; TNFSF6; tumor necrosis factor (ligand) superfamily, member 6; ALPS1B; APTL; CD95-L; CD ...... |
Chromosomal Location | 1q23 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting FASLG collected from DrugBank database. |
There is no record. |